{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:34:03Z","timestamp":1792989243182,"version":"4.5.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40256-025-00762-9","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T12:13:24Z","timestamp":1756556004000},"page":"35-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4004-9290","authenticated-orcid":false,"given":"Kayode","family":"Ogunniyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-8824","authenticated-orcid":false,"given":"Chukwuemeka Christian","family":"Aghasili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-4919","authenticated-orcid":false,"given":"Olumide","family":"Akinmoju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0746-8552","authenticated-orcid":false,"given":"Victor Olamiposi","family":"Olaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5940-842X","authenticated-orcid":false,"given":"Oluwamisimi","family":"Abib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-2651","authenticated-orcid":false,"given":"Adetayo Y.","family":"Odueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6108-9497","authenticated-orcid":false,"given":"Hakeem Adegboyega","family":"Popoola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-9898","authenticated-orcid":false,"given":"Victor","family":"Onyenokwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1306-5475","authenticated-orcid":false,"given":"David","family":"Onaolapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-264X","authenticated-orcid":false,"given":"Abdul-Azeez Muhammed","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toluwalase","family":"Awoyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Nfonoyim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rotatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"32","key":"762_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"9493","key":"762_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"1","key":"762_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14797\/mdcj-15-1-23","volume":"15","author":"PP Toth","year":"2019","unstructured":"Toth PP, Banach M. Statins: then and now. Methodist Debakey Cardiovasc J. 2019;15(1):23\u201331.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"8934","key":"762_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(94)90566-5","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(94)90566-5.","journal-title":"Lancet"},{"issue":"1","key":"762_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63598-4","volume":"14","author":"HP Wu","year":"2024","unstructured":"Wu HP, Yang FC, Lin HD, Cai CZ, Chuang MJ, Chiang KF, et al. Association between statin therapy and long-term clinical outcomes in patients with stable coronary disease undergoing percutaneous coronary intervention. Sci Rep. 2024;14(1): 12674.","journal-title":"Sci Rep"},{"issue":"2","key":"762_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.mayocp.2023.09.016","volume":"99","author":"NS Shetty","year":"2024","unstructured":"Shetty NS, Gaonkar M, Patel N, Knowles JW, Natarajan P, Arora G, et al. Trends of lipid concentrations, awareness, evaluation, and treatment in severe dyslipidemia in US adults. Mayo Clin Proc. 2024;99(2):271\u201382.","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"762_CR7","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","volume":"137","author":"KV Patel","year":"2018","unstructured":"Patel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018;137(24):2551\u20133.","journal-title":"Circulation"},{"issue":"12","key":"762_CR8","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1111\/bcp.14333","volume":"86","author":"RC Rezende Macedo do Nascimento","year":"2020","unstructured":"Rezende Macedo do Nascimento RC, Mueller T, Godman B, MacBride Stewart S, Hurding S, de Assis Acurcio F, et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study. Br J Clin Pharmacol. 2020;86(12):2349\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"762_CR9","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.117.032321","volume":"137","author":"EM Bucholz","year":"2018","unstructured":"Bucholz EM, Rodday AM, Kolor K, Khoury MJ, de Ferranti SD. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999\u20132014). Circulation. 2018;137(21):2218\u201330.","journal-title":"Circulation"},{"issue":"316","key":"762_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijcard.2020.05.055","volume":"1","author":"L De Luca","year":"2020","unstructured":"De Luca L, Arca M, Temporelli PL, Meessen J, Riccio C, Bonomo P, et al. Current lipid lowering treatment and attainment of LDL targets recommended by ESC\/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. Int J Cardiol. 2020;1(316):229\u201335.","journal-title":"Int J Cardiol"},{"issue":"8","key":"762_CR11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2022.1876","volume":"7","author":"MB Mortensen","year":"2022","unstructured":"Mortensen MB, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Statin eligibility for primary prevention of cardiovascular disease according to 2021 European Prevention Guidelines compared with other international guidelines. JAMA Cardiol. 2022;7(8):836\u201343.","journal-title":"JAMA Cardiol."},{"issue":"14","key":"762_CR12","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366\u2013418.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"762_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101342","volume":"47","author":"T Abdul-Rahman","year":"2022","unstructured":"Abdul-Rahman T, Bukhari SMA, Herrera EC, Awuah WA, Lawrence J, de Andrade H, et al. Lipid lowering therapy: an era beyond statins. Curr Probl Cardiol. 2022;47(12): 101342.","journal-title":"Curr Probl Cardiol"},{"issue":"9","key":"762_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12170-022-00694-y","volume":"16","author":"SP Gaine","year":"2022","unstructured":"Gaine SP, Quispe R, Patel J, Michos ED. New strategies for lowering low density lipoprotein cholesterol for cardiovascular disease prevention. Curr Cardiovasc Risk Rep. 2022;16(9):69\u201378.","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"762_CR15","first-page":"415","volume":"8","author":"BAP Phan","year":"2012","unstructured":"Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415\u201327.","journal-title":"Vasc Health Risk Manag"},{"issue":"15","key":"762_CR16","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571\u201382.","journal-title":"Circulation"},{"issue":"12","key":"762_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","volume":"140","author":"Y Ouchi","year":"2019","unstructured":"Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation. 2019;140(12):992\u20131003.","journal-title":"Circulation"},{"issue":"10349","key":"762_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390.","journal-title":"Lancet"},{"issue":"15","key":"762_CR19","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","volume":"85","author":"M Leosdottir","year":"2025","unstructured":"Leosdottir M, Schubert J, Brandts J, Gustafsson S, Cars T, Sundstr\u00f6m J, et al. Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART Registry. J Am Coll Cardiol. 2025;85(15):1550\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"762_CR20","first-page":"474","volume":"38","author":"A Mahmoud","year":"2025","unstructured":"Mahmoud A, Mohamed Salamah H, Rezq H, Al-Mohtasib Y, Ashraf Salah Ahmed A, Abdelraouf MR, et al. Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(4):474\u201383.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"24","key":"762_CR21","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285-350.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"762_CR22","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"5","key":"762_CR23","first-page":"196","volume":"12","author":"A Elshafeey","year":"2025","unstructured":"Elshafeey A. Therapeutic management of LDL-C: efficacy and economic impact assessment. J Cardiovasc Dev Dis. 2025;12(5):196.","journal-title":"J Cardiovasc Dev Dis."},{"issue":"15","key":"762_CR24","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"5","key":"762_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11(5):367\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"762_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.06.971","volume":"378","author":"R Marfella","year":"2023","unstructured":"Marfella R, Prattichizzo F, Sardu C, Paolisso P, D\u2019Onofrio N, Scisciola L, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023;378: 117180.","journal-title":"Atherosclerosis"},{"issue":"18","key":"762_CR27","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"762_CR28","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"8","key":"762_CR29","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/dom.15650","volume":"26","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials. Diabetes Obes Metab. 2024;26(8):3223\u201337.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"762_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40256-024-00712-x","volume":"25","author":"T Mansoor","year":"2025","unstructured":"Mansoor T, Rao BH, Gupta K, Parikh SS, Abramov D, Mehta A, et al. Inclisiran as a siRNA inhibitor of proprotein convertase subtilisin\/kexin type 9 (PCSK9); past, present, and future. Am J Cardiovasc Drugs. 2025;25(3):293\u2013306.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"21","key":"762_CR31","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","volume":"85","author":"MJ Koren","year":"2025","unstructured":"Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, et al. An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial. J Am Coll Cardiol. 2025;85(21):1996\u20132007.","journal-title":"J Am Coll Cardiol"},{"key":"762_CR32","unstructured":"Ce K, A ME, A S, D S, E H, Pd M, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases (Basel, Switzerland) [Internet]. 2018 Jul 13 [cited 2025 Jul 25];6(3). https:\/\/pubmed.ncbi.nlm.nih.gov\/30011788\/. Accessed 25 July 2025."},{"issue":"5","key":"762_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/FJC.0000000000001404","volume":"81","author":"OM Kim","year":"2023","unstructured":"Kim OM, Givens TK, Tang EG, Schimmer JJ, Ramsey T, Boyd K, et al. Real-world outcomes of proprotein convertase subtilisin kexin-9 inhibitor use. J Cardiovasc Pharmacol. 2023;81(5):339\u201347.","journal-title":"J Cardiovasc Pharmacol"},{"key":"762_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001731","author":"G Santulli","year":"2022","unstructured":"Santulli G, Kansakar U, Jankauskas SS, Varzideh F. Comparative LDL-C lowering efficacy of non-statin therapies: inclisiran is better than ezetimibe, PCSK9 inhibitors, and bempedoic acid. J Cardiovasc Pharmacol. 2022. https:\/\/doi.org\/10.1097\/FJC.0000000000001731.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"762_CR35","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"28","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;28(7):13457.","journal-title":"Nat Commun"},{"issue":"11","key":"762_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"762_CR37","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"15","key":"762_CR38","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"2","key":"762_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","volume":"84","author":"AM Lincoff","year":"2024","unstructured":"Lincoff AM, Ray KK, Sasiela WJ, Haddad T, Nicholls SJ, Li N, et al. Comparative cardiovascular benefits of bempedoic acid and statin Drugs. J Am Coll Cardiol. 2024;84(2):152\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"762_CR40","unstructured":"Nexlizet (bempedoic acid and ezetimibe) FDA approval history [Internet]. Drugs.com. [cited 2025 Jul 26]. https:\/\/www.drugs.com\/history\/nexlizet.html. Accessed 26 July 2025."},{"issue":"7","key":"762_CR41","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7): e011662.","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"762_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2840-13-26","volume":"24","author":"JC Fruchart","year":"2014","unstructured":"Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;24(13):26.","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl C","key":"762_CR43","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","volume":"18","author":"R Ferrari","year":"2016","unstructured":"Ferrari R, Aguiar C, Alegria E, Bonadonna RC, Cosentino F, Elisaf M, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016;18(Suppl C):C2-12.","journal-title":"Eur Heart J Suppl."},{"issue":"14","key":"762_CR44","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"762_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","volume":"67","author":"RC Hoogeveen","year":"2021","unstructured":"Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem. 2021;67(1):143\u201353.","journal-title":"Clin Chem"},{"key":"762_CR46","doi-asserted-by":"crossref","unstructured":"Jackson EJ, Willard KE, Ballantyne CM. LDL Cholesterol management simplified in (adults)\u2014lower for longer is better: guidance from the National Lipid Association. J Clin Lipidol [Internet]. 2025 Jun 18 [cited 2025 Jul 25]. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1933287425003174. Accessed 25 July 2025.","DOI":"10.1016\/j.jacl.2025.06.002"},{"issue":"13","key":"762_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134312","volume":"12","author":"E Al Mousa","year":"2023","unstructured":"Al Mousa E, Al-Azzam S, Araydah M, Karasneh R, Ghnaimat M, Al-Makhamreh H, et al. A Jordanian multidisciplinary consensus statement on the management of dyslipidemia. J Clin Med. 2023;12(13): 4312.","journal-title":"J Clin Med"},{"key":"762_CR48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pcad.2024.05.004","volume":"84","author":"GP Soroosh","year":"2024","unstructured":"Soroosh GP, Tasdighi E, Adhikari R, Blaha MJ. Coronary artery calcium in 2023: guidelines for LDL-C goals, non-statin therapies, and aspirin use. Prog Cardiovasc Dis. 2024;84:2\u20136.","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"762_CR49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361\u201375.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"762_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.17925\/EE.2022.18.2.89","volume":"18","author":"MS Jeeyavudeen","year":"2022","unstructured":"Jeeyavudeen MS, Pappachan JM, Arunagirinathan G. Statin-related muscle toxicity: an evidence-based review. touchREV Endocrinol. 2022;18(2):89\u201395.","journal-title":"touchREV Endocrinol."},{"issue":"9","key":"762_CR51","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","volume":"36","author":"AM Mueller","year":"2021","unstructured":"Mueller AM, Liakoni E, Schneider C, Burkard T, Jick SS, Kr\u00e4henb\u00fchl S, et al. The risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study. J Gen Intern Med. 2021;36(9):2639\u201347.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"762_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007480","volume":"14","author":"J Moon","year":"2021","unstructured":"Moon J, Cohen Sedgh R, Jackevicius CA. Examining the nocebo effect of statins through statin adverse events reported in the Food and Drug Administration adverse event reporting system. Circ Cardiovasc Qual Outcomes. 2021;14(1): e007480.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"762_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062444","volume":"12","author":"G Bosco","year":"2023","unstructured":"Bosco G, Di Giacomo Barbagallo F, Spampinato S, Lanzafame L, Di Pino A, Piro S, et al. Management of statin intolerant patients in the era of novel lipid lowering therapies: a critical approach in clinical practice. J Clin Med. 2023;12(6): 2444.","journal-title":"J Clin Med"},{"key":"762_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117550","volume":"393","author":"I Engebretsen","year":"2024","unstructured":"Engebretsen I, Bugge C, St\u00f8vring H, Husebye E, Sverre E, Dammen T, et al. Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event. Atherosclerosis. 2024;393: 117550.","journal-title":"Atherosclerosis"},{"key":"762_CR55","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/PPA.S245365","volume":"14","author":"MV Ingersgaard","year":"2020","unstructured":"Ingersgaard MV, Helms Andersen T, Norgaard O, Grabowski D, Olesen K. Reasons for nonadherence to statins\u2014a systematic review of reviews. Patient Prefer Adherence. 2020;14:675\u201391.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"762_CR56","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","volume":"113","author":"W Koenig","year":"2024","unstructured":"Koenig W, Lorenz ES, Beier L, Gouni-Berthold I. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Clin Res Cardiol. 2024;113(6):812\u201321.","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"762_CR57","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1016\/j.pec.2022.06.013","volume":"105","author":"M Papus","year":"2022","unstructured":"Papus M, Dima AL, Viprey M, Schott AM, Schneider MP, Novais T. Motivational interviewing to support medication adherence in adults with chronic conditions: systematic review of randomized controlled trials. Patient Educ Couns. 2022;105(11):3186\u2013203.","journal-title":"Patient Educ Couns"},{"issue":"3","key":"762_CR58","first-page":"35","volume":"14","author":"R Ratnawati","year":"2024","unstructured":"Ratnawati R, Jumari J, Pratama EF, Syahrir A, Usman RD, Hadi I. The effect of motivational interviewing and family support on self-management in type 2 diabetes mellitus patients. Evidence Based Care. 2024;14(3):35\u201343.","journal-title":"Evidence Based Care."},{"issue":"10","key":"762_CR59","first-page":"1053","volume":"25","author":"SM Abughosh","year":"2019","unstructured":"Abughosh SM, Vadhariya A, Johnson ML, Essien EJ, Esse TW, Serna O, et al. Enhancing statin adherence using a motivational interviewing intervention and past adherence trajectories in patients with suboptimal adherence. J Manag Care Spec Pharm. 2019;25(10):1053\u201362.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"762_CR60","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1262-3636(07)70316-6","volume":"32","author":"Y Bezie","year":"2006","unstructured":"Bezie Y, Molina M, Hernandez N, Batista R, Niang S, Huet D. Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes. Diabetes Metab. 2006;32(6):611\u20136.","journal-title":"Diabetes Metab"},{"key":"762_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2020.00085","volume":"10","author":"M Taberna","year":"2020","unstructured":"Taberna M, Gil Moncayo F, Jan\u00e9-Salas E, Antonio M, Arribas L, Vilajosana E, et al. The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020;10:85.","journal-title":"Front Oncol"},{"key":"762_CR62","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/VHRM.S338424","volume":"19","author":"MS Albosta","year":"2023","unstructured":"Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc Health Risk Manag. 2023;19:421\u201331.","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"762_CR63","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/09546634.2020.1753642","volume":"33","author":"EK Collier","year":"2022","unstructured":"Collier EK, Price KN, Hsiao JL, Shi VY. Demystifying pharmaceutical patient assistance programs. J Dermatol Treat. 2022;33(1):336\u201341.","journal-title":"J Dermatol Treat"},{"issue":"23","key":"762_CR64","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73(23):2961\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"762_CR65","unstructured":"Bempics\u2014Searle [Internet]. [cited 2025 Jul 25]. https:\/\/searlecompany.com\/products\/bempics\/. Accessed 25 July 2025."},{"key":"762_CR66","unstructured":"Bempedoic acid Interactions [Internet]. Drugs.com. [cited 2025 Jul 25]. https:\/\/www.drugs.com\/drug-interactions\/bempec-acid.html. Accessed 25 July 2025."},{"issue":"16","key":"762_CR67","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"2","key":"762_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/hex.14043","volume":"27","author":"L Zhang","year":"2024","unstructured":"Zhang L, Chen J, Cao Z, Zhang M, Ma R, Zhang P, et al. Patient versus physician preferences for lipid-lowering drug therapy: a discrete choice experiment. Health Expect. 2024;27(2): e14043.","journal-title":"Health Expect"},{"issue":"9","key":"762_CR69","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"key":"762_CR70","unstructured":"Foreword | Guide to the methods of technology appraisal 2013 | Guidance | NICE [Internet]. NICE; 2013 [cited 2025 Jul 25]. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword. Accessed 25 July 2025."},{"issue":"4","key":"762_CR71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M18-1776","volume":"170","author":"DS Kazi","year":"2019","unstructured":"Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-Effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med. 2019;170(4):221\u20139.","journal-title":"Ann Intern Med"},{"issue":"10","key":"762_CR72","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"GC Fonarow","year":"2017","unstructured":"Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(10):1069\u201378.","journal-title":"JAMA Cardiol."},{"key":"762_CR73","unstructured":"Overview | Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | Guidance | NICE [Internet]. NICE; 2016 [cited 2025 Jul 25]. https:\/\/www.nice.org.uk\/guidance\/TA394. Accessed 25 July 2025."},{"key":"762_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1284562\/full","author":"C Gier","year":"2024","unstructured":"Gier C, Gilchrist I, Fordham M, Riordan L, Milchan E, Patel N, et al. The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience. Front Cardiovasc Med [Internet]. 2024. https:\/\/doi.org\/10.3389\/fcvm.2024.1284562\/full.","journal-title":"Front Cardiovasc Med [Internet]."},{"issue":"47","key":"762_CR75","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791\u2013806.","journal-title":"Eur Heart J"},{"key":"762_CR76","unstructured":"Harrison\u2019s Principles of Internal Medicine, 21e | AccessMedicine | McGraw Hill Medical [Internet]. [cited 2025 Jul 25]. https:\/\/accessmedicine.mhmedical.com\/book.aspx?bookid=3095&isMissingChapter=true. Accessed 25 July 2025."},{"issue":"3","key":"762_CR77","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"762_CR78","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1194\/jlr.M066399","volume":"57","author":"X Yang","year":"2016","unstructured":"Yang X, Lee SR, Choi YS, Alexander VJ, Digenio A, Yang Q, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57(4):706\u201313.","journal-title":"J Lipid Res"},{"issue":"6","key":"762_CR79","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jacl.2022.06.011","volume":"16","author":"M Lightbourne","year":"2022","unstructured":"Lightbourne M, Startzell M, Bruce KD, Brite B, Muniyappa R, Skarulis M, et al. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy. J Clin Lipidol. 2022;16(6):850\u201362.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"762_CR80","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342.","journal-title":"N Engl J Med"},{"issue":"8","key":"762_CR81","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408\u201315.","journal-title":"Diabetes Care"},{"key":"762_CR82","unstructured":"Waylivra | European Medicines Agency (EMA) [Internet]. 2019 [cited 2025 Jul 25]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/waylivra. Accessed 25 July 2025."},{"key":"762_CR83","unstructured":"FDA nixes Akcea\u2019s volanesorsen despite favorable AdComm | Fierce Biotech [Internet]. [cited 2025 Jul 25]. https:\/\/www.fiercebiotech.com\/biotech\/fda-nixes-akcea-s-volanesorsen-despite-favorable-adcomm. Accessed 25 July 2025."},{"key":"762_CR84","unstructured":"Research C for DE and. FDA approves drug to reduce triglycerides in adult patients with familial chylomicronemia syndrome. FDA [Internet]. 2024 Dec 19 [cited 2025 Jul 25]. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chylomicronemia-syndrome. Accessed 25 July 2025."},{"issue":"19","key":"762_CR85","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781\u201392.","journal-title":"N Engl J Med"},{"issue":"19","key":"762_CR86","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390(19):1770\u201380.","journal-title":"N Engl J Med"},{"issue":"17","key":"762_CR87","doi-asserted-by":"publisher","first-page":"13622","DOI":"10.3390\/ijms241713622","volume":"24","author":"CE Kosmas","year":"2023","unstructured":"Kosmas CE, Bousvarou MD, Papakonstantinou EJ, Tsamoulis D, Koulopoulos A, Echavarria Uceta R, et al. Novel pharmacological therapies for the management of hyperlipoproteinemia(a). Int J Mol Sci. 2023;24(17):13622.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"762_CR88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40256-021-00499-1","volume":"22","author":"J Hardy","year":"2022","unstructured":"Hardy J, Niman S, Goldfaden RF, Ashchi M, Bisharat M, Huston J, et al. A review of the clinical pharmacology of pelacarsen: a lipoprotein(a)-lowering agent. Am J Cardiovasc Drugs. 2022;22(1):47\u201354.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"762_CR89","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","volume":"79","author":"C Yeang","year":"2022","unstructured":"Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"762_CR90","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","volume":"81","author":"WA Malick","year":"2023","unstructured":"Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical trial design for lipoprotein(a)-lowering therapies: JACC Focus Seminar 2\/3. J Am Coll Cardiol. 2023;81(16):1633\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"762_CR91","unstructured":"IONIS PHARMACEUTICALS INC (Form: 10-K, Received: 02\/21\/2024 20:04:15) [Internet]. [cited 2025 Jul 25]. https:\/\/content.edgar-online.com\/ExternalLink\/EDGAR\/0000874015-24-000116.html?hash=706e4b0c5f6ea6409c981dcf01ca47ebba1f0dcfdbcda8039d445627df01fe44&dest=form10k_htm#form10k_htm. Accessed 25 July 2025."},{"issue":"2","key":"762_CR92","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4093\/dmj.2015.39.2.87","volume":"39","author":"CH Ahn","year":"2015","unstructured":"Ahn CH, Choi SH. New drugs for treating dyslipidemia: beyond statins. Diabetes Metab J. 2015;39(2):87\u201394.","journal-title":"Diabetes Metab J"},{"issue":"7","key":"762_CR93","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","volume":"79","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials. Drugs. 2019;79(7):751\u201366.","journal-title":"Drugs"},{"key":"762_CR94","unstructured":"Hamada M, Farzam K. Mipomersen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jul 25]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK592392\/. Accessed 25 July 2025."},{"issue":"2","key":"762_CR95","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","volume":"20","author":"JS Parham","year":"2019","unstructured":"Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother. 2019;20(2):127\u201331.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"762_CR96","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/pharma3010009","volume":"3","author":"T Kayani","year":"2024","unstructured":"Kayani T, Ahmad B, Chang RS, Qian F, Sahinoz M, Rehan MW, et al. Beyond statins: novel lipid-lowering agents for reducing risk of atherosclerotic cardiovascular disease. Pharmacoepidemiology. 2024;3(1):117\u201368.","journal-title":"Pharmacoepidemiology"},{"key":"762_CR97","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ahj.2020.10.052","volume":"231","author":"CM Gibson","year":"2021","unstructured":"Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, et al. Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. Am Heart J. 2021;231:121\u20137.","journal-title":"Am Heart J"},{"issue":"9943","key":"762_CR98","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","volume":"384","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384(9943):618\u201325.","journal-title":"Lancet"},{"issue":"4","key":"762_CR99","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ehjcvp\/pvad014","volume":"9","author":"S Korjian","year":"2023","unstructured":"Korjian S, Kazmi SHA, Chi G, Kalayci A, Lee JJ, Talib U, et al. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2023;9(4):387\u201398.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"24","key":"762_CR100","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.116.025687","volume":"134","author":"C Michael Gibson","year":"2016","unstructured":"Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in ischemic syndromes I). Circulation. 2016;134(24):1918\u201330.","journal-title":"Circulation"},{"issue":"3","key":"762_CR101","first-page":"39","volume":"5","author":"MG Lupo","year":"2018","unstructured":"Lupo MG, Ferri N. Angiopoietin-like 3 (ANGPTL3) and atherosclerosis: lipid and non-lipid related effects. J Cardiovasc Dev Dis. 2018;5(3):39.","journal-title":"J Cardiovasc Dev Dis."},{"issue":"8","key":"762_CR102","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"key":"762_CR103","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","volume":"327","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp LF, Nurmohamed NS, Bom MJ, Planken RN, Driessen RS, van Diemen PA, et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 2021;327:13\u20137.","journal-title":"Atherosclerosis"},{"issue":"5","key":"762_CR104","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343\u201353.","journal-title":"Circulation"},{"issue":"27","key":"762_CR105","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","volume":"45","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, et al. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024;45(27):2422\u201334.","journal-title":"Eur Heart J"},{"key":"762_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70016","author":"S Bihorel","year":"2025","unstructured":"Bihorel S, Dingman R, Mendell J, Wang Y, Banerjee P, Pordy R, Davis JD, DiCioccio AT, Harnisch L. Population pharmacokinetics and exposure-response modeling for evinacumab in children, adolescents, and adults with homozygous familial hypercholesterolemia. CPT Pharmacometr Syst Pharmacol. 2025. https:\/\/doi.org\/10.1002\/psp4.70016","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"2","key":"762_CR107","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","volume":"26","author":"JJP Kastelein","year":"2024","unstructured":"Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib: reversing the tide of CETP inhibitor disappointments. Curr Atheroscler Rep. 2024;26(2):35\u201344.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"762_CR108","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/ehjcvp\/pvac056","volume":"9","author":"SS Martin","year":"2023","unstructured":"Martin SS, Ditmarsch M, Simmons M, Alp N, Turner T, Davidson MH, et al. Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):148\u201355.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"8","key":"762_CR109","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"762_CR110","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491\u2013503.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"762_CR111","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.5551\/jat.64828","volume":"31","author":"M Harada-Shiba","year":"2024","unstructured":"Harada-Shiba M, Davdison MH, Ditmarsch M, Hsieh A, Wuerdeman E, Kling D, et al. Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial. J Atheroscler Thromb. 2024;31(10):1386\u201397.","journal-title":"J Atheroscler Thromb"},{"key":"762_CR112","unstructured":"Sj N, Aj N, M D, Jjp K, Cm B, Kk R, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Eng J Med [Internet]. 2025 Jul 3 [cited 2025 Jul 26];393(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/40337982\/. Accessed 26 July 2025."},{"key":"762_CR113","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","volume":"274","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, et al. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024;274:32\u201345.","journal-title":"Am Heart J"},{"key":"762_CR114","unstructured":"Obicetrapib in atherosclerotic cardiovascular disease\u2014Clinical Trials Registry\u2014ICH GCP [Internet]. [cited 2025 Jul 26]. https:\/\/ichgcp.net\/clinical-trials-registry\/NCT05202509. Accessed 26 July 2025."},{"issue":"966","key":"762_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176338","volume":"5","author":"A Attiq","year":"2024","unstructured":"Attiq A, Afzal S, Ahmad W, Kandeel M. Hegemony of inflammation in atherosclerosis and coronary artery disease. Eur J Pharmacol. 2024;5(966): 176338.","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"762_CR116","doi-asserted-by":"publisher","first-page":"12109","DOI":"10.3390\/ijms222212109","volume":"22","author":"A Gluba-Brz\u00f3zka","year":"2021","unstructured":"Gluba-Brz\u00f3zka A, Franczyk B, Rysz-G\u00f3rzy\u0144ska M, \u0141awi\u0144ski J, Rysz J. Emerging anti-atherosclerotic therapies. Int J Mol Sci. 2021;22(22):12109.","journal-title":"Int J Mol Sci"},{"issue":"10289","key":"762_CR117","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139.","journal-title":"Lancet"},{"issue":"3","key":"762_CR118","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40119-024-00376-3","volume":"13","author":"R Zubir\u00e1n","year":"2024","unstructured":"Zubir\u00e1n R, Neufeld EB, Dasseux A, Remaley AT, Sorokin AV. Recent advances in targeted management of inflammation in atherosclerosis: a narrative review. Cardiol Ther. 2024;13(3):465\u201391.","journal-title":"Cardiol Ther"},{"issue":"11","key":"762_CR119","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","volume":"117","author":"PM Ridker","year":"2021","unstructured":"Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117(11):e138\u201340.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"762_CR120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4244\/EIJ-D-23-00606","volume":"20","author":"R Waksman","year":"2024","unstructured":"Waksman R, Merdler I, Case BC, Waksman O, Porto I. Targeting inflammation in atherosclerosis: overview, strategy and directions. EuroIntervention. 2024;20(1):32\u201344.","journal-title":"EuroIntervention"},{"issue":"7","key":"762_CR121","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","volume":"19","author":"BN Weber","year":"2023","unstructured":"Weber BN, Giles JT, Liao KP. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat Rev Rheumatol. 2023;19(7):417\u201328.","journal-title":"Nat Rev Rheumatol"},{"issue":"6096","key":"762_CR122","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321.","journal-title":"Science"},{"issue":"16","key":"762_CR123","doi-asserted-by":"publisher","first-page":"8422","DOI":"10.3390\/ijms22168422","volume":"22","author":"WS Siew","year":"2021","unstructured":"Siew WS, Tang YQ, Kong CK, Goh BH, Zacchigna S, Dua K, et al. Harnessing the potential of CRISPR\/Cas in atherosclerosis: disease modeling and therapeutic applications. Int J Mol Sci. 2021;22(16):8422.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"762_CR124","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023;8(1):36.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"762_CR125","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","volume":"141","author":"H Zhao","year":"2020","unstructured":"Zhao H, Li Y, He L, Pu W, Yu W, Li Y, et al. In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation. 2020;141(1):67\u201379.","journal-title":"Circulation"},{"issue":"11","key":"762_CR126","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","volume":"2","author":"AM Navar","year":"2017","unstructured":"Navar AM, Taylor B, Mulder H, Fievitz E, Monda KL, Fievitz A, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2(11):1217\u201325.","journal-title":"JAMA Cardiol."},{"issue":"Supplement_1","key":"762_CR127","doi-asserted-by":"publisher","first-page":"zwac056.165","DOI":"10.1093\/eurjpc\/zwac056.165","volume":"29","author":"S Brennan","year":"2022","unstructured":"Brennan S, Mc Evoy JW. Bempedoic acid and PCSK9 inhibitor eligibility in a contemporary population with atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2022;29(Supplement_1):zwac056.165.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"762_CR128","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","volume":"11","author":"JD Cohen","year":"2017","unstructured":"Cohen JD, Cziraky MJ, Jacobson TA, Maki KC, Karalis DG. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association. J Clin Lipidol. 2017;11(4):891\u2013900.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"762_CR129","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005404","volume":"12","author":"KD Myers","year":"2019","unstructured":"Myers KD, Farboodi N, Mwamburi M, Howard W, Staszak D, Gidding S, et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. Circ Cardiovasc Qual Outcomes. 2019;12(8): e005404.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"762_CR130","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2017.07.004","volume":"55","author":"T Yezefski","year":"2018","unstructured":"Yezefski T, Schwemm A, Lentz M, Hone K, Shankaran V. Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. Semin Hematol. 2018;55(4):185\u20138.","journal-title":"Semin Hematol"},{"key":"762_CR131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.12688\/wellcomeopenres.16593.1","volume":"6","author":"LW Mwangi","year":"2021","unstructured":"Mwangi LW, Abuga JA, Cottrell E, Kariuki SM, Kinyanjui SM, Newton CR. Barriers to access and utilization of healthcare by children with neurological impairments and disability in low-and middle-income countries: a systematic review. Wellcome Open Res. 2021;6:61.","journal-title":"Wellcome Open Res"},{"key":"762_CR132","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1196\/annals.1425.011","volume":"1136","author":"DH Peters","year":"2008","unstructured":"Peters DH, Garg A, Bloom G, Walker DG, Brieger WR, Rahman MH. Poverty and access to health care in developing countries. Ann N Y Acad Sci. 2008;1136:161\u201371.","journal-title":"Ann N Y Acad Sci"},{"key":"762_CR133","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.publhealth.012809.103649","volume":"31","author":"RD Gibbons","year":"2010","unstructured":"Gibbons RD, Amatya AK, Brown CH, Hur K, Marcus SM, Bhaumik DK, et al. Post-approval drug safety surveillance. Annu Rev Public Health. 2010;31:419\u201337.","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"762_CR134","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40264-018-0766-8","volume":"42","author":"F Liu","year":"2019","unstructured":"Liu F, Jagannatha A, Yu H. Towards drug safety surveillance and pharmacovigilance: current progress in detecting medication and adverse drug events from electronic health records. Drug Saf. 2019;42(1):95\u20137.","journal-title":"Drug Saf"},{"issue":"12","key":"762_CR135","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jamda.2021.05.038","volume":"22","author":"J Ruiz-Ramos","year":"2021","unstructured":"Ruiz-Ramos J, Hern\u00e1ndez MH, Juanes-Borrego AM, Mil\u00e0 R, Mangues-Bafalluy MA, Mestres C. The impact of pharmaceutical care in multidisciplinary teams on health outcomes: systematic review and meta-analysis. J Am Med Dir Assoc. 2021;22(12):2518\u201326.","journal-title":"J Am Med Dir Assoc"},{"issue":"12","key":"762_CR136","first-page":"1116","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2017;377(12):1116\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"762_CR137","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","volume":"390","author":"JL Witztum","year":"2024","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia. N Engl J Med. 2024;390(5):476\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"762_CR138","first-page":"555","volume":"13","author":"I Gouni-Berthold","year":"2019","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Liu M, Hovingh GK, et al. Efficacy and safety of volanesorsen in severe hypertriglyceridemia: results from the COMPASS trial. J Clin Lipidol. 2019;13(5):555\u201365.","journal-title":"J Clin Lipidol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00762-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:03:12Z","timestamp":1767801792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00762-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00762-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive funding from any public, commercial, or not-for-profit funding agencies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kayode Ogunniyi, Chukwuemeka Christian Aghasili, Olumide Akinmoju, Victor Olamiposi Olaiya, Oluwamisimi Abib, Adetayo Y. Odueke, Hakeem Adegboyega Popoola, Victor Onyenokwe, David Onaolapo, Abdul\u2011Azeez Muhammed Usman, Adam Friedman,  Toluwalase Awoyemi, Jay Nfonoyim, and Francesco Rotatori declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable. This article is a narrative review and does not involve human or animal subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Kayode Ogunniyi conceptualized the article, convened the writing group, coordinated the collaborative process, and drafted the initial manuscript. All co-authors contributed to the literature search, data synthesis, and manuscript development. Jay Nfonoyim and Francesco Rotatori provided senior supervision and critical revision of the work. All authors reviewed and approved the final version of the manuscript","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable. No new data were created or analyzed in this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}